Neuronetics stock: Revenue rises as quarterly loss narrows

Published on 11/05/2026 at 13:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Neuronetics stock follows a quarter of stronger revenue and improved profitability. Management kept its full-year revenue outlook unchanged.

Revenue Growth and Profitability Improve

Third-quarter revenue rose 12.5% year over year, driven by a 20.1% increase in Greenbrook revenue.
Adjusted EBITDA turned positive, while the company narrowed its net loss and generated positive operating and investing cash flow.
Neuronetics maintained its 2026 revenue outlook and raised the low end of its gross-margin range.

STIM, US64131A1051, Illustration mit AI erstellt.

Neuronetics reported stronger operating performance for the third quarter ended September 30, 2026, in a release issued Wednesday, November 4. According to the Neuronetics release published by GlobeNewswire, revenue reached $41.962 million, up 12.5% from the year-earlier quarter.

Greenbrook Drives Quarterly Growth

Greenbrook revenue increased 20.1% to $26.192 million, while NeuroStar revenue rose 1.8% to $15.770 million. The company attributed the overall increase primarily to continued growth in its Greenbrook clinic business.

Gross margin expanded to 52.2% from 45.9% a year earlier. Operating expenses declined to $21.349 million from $24.429 million, helping income from operations turn positive at $0.541 million compared with a $7.321 million loss in the third quarter of 2025.

Loss Narrows As EBITDA Turns Positive

Net loss attributable to Neuronetics stockholders narrowed to $1.692 million, or $0.02 per share, from $9.045 million, or $0.13 per share. Adjusted EBITDA improved to $1.887 million from a loss of $4.670 million; the company labels this measure non-GAAP.

Cash provided by operating and investing activities was $0.8 million, compared with an outflow of $0.9 million in the prior-year quarter. Total cash stood at $27.9 million on September 30, including $22.1 million in cash and cash equivalents and $5.8 million in restricted cash.

Outlook Stays Broadly Intact

Neuronetics kept its 2026 revenue outlook at $160 million to $164 million. It now expects a gross margin of 49% to 50%, compared with the previous 48% to 50% range, and forecasts operating expenses of $92.5 million to $95.5 million.

The company also narrowed its expected 2026 cash flow from operating and investing activities to an outflow of $10 million to $12 million, from the previous range of $10.5 million to $14.5 million. Management said an AdvancedMD EHR and practice-management integration is expected to become available to existing NeuroStar providers in the fourth quarter.

Neuronetics stock traded at 2.48 euros on Lang & Schwarz at 1:29 p.m. CET on Thursday, November 5, 2026. Investors can follow the real-time quote of Neuronetics stock.